Elsevier

JAAD Case Reports

Volume 5, Issue 4, April 2019, Pages 365-367
JAAD Case Reports

Case report
Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata

https://doi.org/10.1016/j.jdcr.2019.02.007Get rights and content
Under a Creative Commons license
open access

Key words

alopecia areata
atopic dermatitis
autoimmunity
Down syndrome
eczema
interferon
Janus kinase inhibition
tofacitnib
vitiligo
Xeljanz
trisomy 21

Abbreviations used

AA
alopecia areata
DS
Down syndrome
IFN
interferon
JAK
Janus kinase
STAT
signal transducer activator of transcription
T21
trisomy 21

Cited by (0)

Funding sources: University of Colorado Linda Crnic Institute for Down Syndrome, Global Down Syndrome Foundation, and the Anna and John J. Sie Foundation.

Conflicts of interest: Dr Cory Dunnick discloses that she is the principal investigator for 2 clinical trials with Pfizer using an investigational JAK inhibitor to treat alopecia areata. All clinical trial reimbursement is paid to the University of Colorado. The rest of the authors have no conflicts to disclose.